• Precigen highlighted long-term durability results for PAPZIMEOS in adult recurrent respiratory papillomatosis, already presented at the 2026 ASCO annual meeting.
• Follow-up showed many patients who fully responded stayed free of additional RRP treatment for years, supporting the drug’s potential to reduce repeat surgeries.
• The FDA granted PAPZIMEOS orphan drug exclusivity, blocking approval of similar RRP therapies for seven years and extending U.S. exclusivity through August 2032.
• The product is already on the U.S. market, with prescribing across major centers and community practices.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606150640ACCESSWRNAPR_____1177080) on June 15, 2026, and is solely responsible for the information contained therein.